Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter
Benzinga
10 Jan
Other Fourth Quarter 2024 Updates
Recorlev achieved record number of new starts and referrals.
Gvoke ended the year with approximately 35% market share.
Keveyis maintained a similar number of patients on therapy as Q3 2024.
Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.
Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.